glucose-6-phosphate dehydrogenase

(redirected from G6PD)
Also found in: Medical, Acronyms, Encyclopedia.
Related to G6PD: G6PD deficiency

glu·cose-6-phos·phate de·hy·dro·gen·ase

n. glucofosfato de deshidrogenasa, enzima presente en el hígado y los riñones necesaria en la conversión de glicerol a glucosa.
English-Spanish Medical Dictionary © Farlex 2012
References in periodicals archive ?
Comment: There have been two previous case reports of acute hemolysis induced by high-dose intravenous vitamin C in patients with G6PD deficiency.
NADPH required for an effective treatment is derived from the hexose monophosphate pathway, therefore, the G6PD level should be normal (15,16).
Safety of primaquine given to people with G6PD deficiency: Systematic review of prospective studies.
Methylene blue (1 mg/kg/body weight)--contraindicated in G6PD deficiency.
Keywords: Glucose-6-phosphate dehydrogenase, G6PD, Hepatitis E, Haemolysis.
(11) By contrast, there are only a few case reports on using oral dapsone as a treatment for severe acne, most likely due to its well-known systemic side effects including hemolytic anemia and methemoglobinemia, which can be prevented by checking G6PD levels before dapsone administration along with close monitoring of the patient by performing regular routine laboratory tests and clinical examinations over time.
--Most common genetic disorders are thalassaemia, sickle cell, anaemia, haemophilia and G6PD deficiency
It is important to consider the possibility of G6PD deficiency in a patient prior to administration of rasburicase, as it can lead to hemolysis in these patients [17].
There is an urgent need to prioritise health services and concentrate on preventative cost-effective measures." The most common hereditary blood disorders in Oman are sickle cell disease (SCD), beta thalassaemia and glucose-6-phosphate dehydrogenase (G6PD) deficiency, Al Balushi mentioned in her recent publication in the Sultan Qaboos University Medical Journal.
Glucose-6-phosphate dehydrogenase (G6PD) activity was within normal limits.
Use of the drug close to term may cause hemolytic anemia in newborns who are glucose-6-phosphate dehydrogenase (G6PD) deficient.
Several maternal and neonatal risk factors such as preeclampsia, G6PD deficiency, ABO incompatibility, prematurity, birth weight, intrauterine growth retardation, metabolic abnormalities, neonate's gender, birth weight, and nutrition have been identified as risk factors for neonatal jaundice [8, 9].